Evidence review · Published July 22, 2026 · Sources checked July 22, 2026

Tesamorelin research overview

Tesamorelin is a stabilized analogue of growth-hormone-releasing hormone designed to activate the pituitary GHRH receptor.

Evidence boundary: published research does not establish the identity or performance of a separately supplied batch. The catalog product is supplied only for qualified in vitro laboratory research and is not for human or animal use.

What is Tesamorelin?

Randomized studies have primarily examined people living with HIV who had excess abdominal adiposity, using characterized clinical material and protocol-defined endpoints.

Research category
Endocrine & receptor signaling
Study models represented
Randomized phase 2 and phase 3 human studies in HIV-associated abdominal adiposity
Names in the literature
TH9507; GHRH analogue
Primary boundary
Population- and protocol-specific findings do not establish general body-composition claims.

What does the selected evidence support?

Those findings should not be generalized to unrelated populations, goals, or research-use-only products.

Primary sources

  1. Falutz et al., Journal of Clinical Endocrinology & Metabolism (2005) — Randomized placebo-controlled dose-ranging study in HIV-associated abdominal fat accumulation. DOI: 10.1210/jc.2005-0495
  2. Falutz et al., New England Journal of Medicine (2007) — Randomized controlled study of metabolic endpoints in a defined HIV population. DOI: 10.1056/NEJMoa071137
  3. Stanley et al., JAMA (2014) — Controlled study examining visceral and liver fat in a defined HIV population. DOI: 10.1001/jama.2014.8334

Research literature and product documentation are different

A publication describes a study and its results. A batch-specific Certificate of Analysis documents characteristics of a supplied research material. One does not substitute for the other.

Review Tesamorelin product specifications · Browse the COA library · Read the research-use policy

Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.